Real-world evidence of ribociclib-induced hepatotoxicity in patients with breast cancer: a multi-center experience
Ribociclib is associated with an increased risk of hepatotoxicity, with the potential for grade 3-4 in a small number of patients. Our analysis suggested a potential association between grade 3-4 hepatotoxicity and reduced OS, warranting further investigation. Regular monitoring of liver function tests during ribociclib treatment may help clinicians identify high-risk patients requiring closer follow-up.
Authors
- Pınar Kubilay Tolunay (ORCID: https://orcid.org/0000-0003-2636-5326)
- Safa Can Efil (ORCID: https://orcid.org/0000-0001-9586-2858)
- Taha Koray Şahin (ORCID: https://orcid.org/0000-0002-3590-0426)
- İmdat Eroğlu (ORCID: https://orcid.org/0000-0001-6619-4141)
- Mehmet Alı Nahıt Şendur (ORCID: https://orcid.org/0000-0001-7021-6139)
- Sercan Aksoy (ORCID: https://orcid.org/0000-0003-4984-1049)
- Onur Baş (ORCID: https://orcid.org/0000-0002-8726-0360)
- Ozan Yazıcı (ORCID: https://orcid.org/0000-0003-2844-0959)
- Bediz Kurt İnci (ORCID: https://orcid.org/0000-0002-6238-0534)
- Seher Kaya (ORCID: https://orcid.org/0000-0001-5418-507X)
- Cengiz Karaçin (ORCID: https://orcid.org/0000-0002-7310-9328)
- Berna Ömür Çakmak Öksüzoğlu
Institutions
- Memorial Ankara Hospital (TR)
- Ankara Onkoloji Eğitim ve Araştırma Hastanesi (TR)
- Hacettepe University (TR)
- Gazi University (TR)
Publication Details
- Journal
- BMC Cancer
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1186/s12885-025-15181-x
- Citations
- 1
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.52